00:12 , May 31, 2019 |  BC Innovations  |  Translation in Brief

New target for Oncoceutics' GPCR-targeting compounds

Two academic teams have discovered Oncoceutics’ GPCR-targeting products kill cancer via an alternative mechanism: triggering apoptosis by activating a mitochondrial protease. Oncoceutics Inc. is developing a pipeline of imipridones to antagonize or agonize GPCRs including...